ECSP17074919A - Piroglutamato de vortioxetina - Google Patents
Piroglutamato de vortioxetinaInfo
- Publication number
- ECSP17074919A ECSP17074919A ECIEPI201774919A ECPI201774919A ECSP17074919A EC SP17074919 A ECSP17074919 A EC SP17074919A EC IEPI201774919 A ECIEPI201774919 A EC IEPI201774919A EC PI201774919 A ECPI201774919 A EC PI201774919A EC SP17074919 A ECSP17074919 A EC SP17074919A
- Authority
- EC
- Ecuador
- Prior art keywords
- vortioxetine pyroglutamate
- vortioxetine
- pyroglutamate
- salt
- provides
- Prior art date
Links
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 title abstract 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002263 vortioxetine Drugs 0.000 title abstract 2
- 229940043131 pyroglutamate Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona sal de piroglutamato de vortioxetina y composiciones farmacéuticas que comprenden dicha sal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500284 | 2015-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17074919A true ECSP17074919A (es) | 2018-02-28 |
Family
ID=55963369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201774919A ECSP17074919A (es) | 2015-05-13 | 2017-11-10 | Piroglutamato de vortioxetina |
Country Status (44)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45532A (fr) | 2016-07-01 | 2019-05-08 | H Lundbeck As | Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| US11020390B2 (en) * | 2017-02-17 | 2021-06-01 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
| CN111201217A (zh) * | 2017-07-31 | 2020-05-26 | 斯玛尔药物有限公司 | 羟基去甲氯胺酮的晶型 |
| GB201715950D0 (en) * | 2017-10-02 | 2017-11-15 | Croda Int Plc | Gel composition comprising a phase change material |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP7874549B2 (ja) | 2020-04-03 | 2026-06-16 | ハー・ルンドベック・アクチエゼルスカベット | 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1006728A (en) * | 1962-12-31 | 1965-10-06 | Mundipharma Ag | Amine salts of pyrrolidone carboxylic acid |
| JPS6160620A (ja) | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
| US4780667A (en) | 1985-06-25 | 1988-10-25 | Hewlett-Packard Company | Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration |
| FR2694194B1 (fr) | 1992-07-31 | 1994-11-04 | Health Business Dev | Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel. |
| JP2000516222A (ja) | 1996-08-15 | 2000-12-05 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング | 嚥下が容易な経口医薬組成物 |
| US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
| SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| US8383154B2 (en) | 2004-05-11 | 2013-02-26 | Egalet A/S | Swellable dosage form comprising gellan gum |
| MY150647A (en) * | 2006-06-16 | 2014-02-14 | Lundbeck & Co As H | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| RS53539B1 (sr) | 2009-04-24 | 2015-02-27 | H. Lundbeck A/S | Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina |
| CA2769872A1 (en) | 2009-08-24 | 2011-03-03 | H. Lundbeck A/S | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine |
| WO2011136376A1 (ja) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
| HRP20170607T1 (hr) | 2013-02-22 | 2017-06-30 | H. Lundbeck A/S | Proizvodni postupak vortioksetina |
-
2016
- 2016-05-10 JO JOP/2016/0091A patent/JO3456B1/ar active
- 2016-05-11 PL PL16721817T patent/PL3294719T3/pl unknown
- 2016-05-11 HU HUE16721817A patent/HUE042893T2/hu unknown
- 2016-05-11 CR CR20170506A patent/CR20170506A/es unknown
- 2016-05-11 WO PCT/EP2016/060540 patent/WO2016180870A1/en not_active Ceased
- 2016-05-11 TN TNP/2017/000453A patent/TN2017000453A1/en unknown
- 2016-05-11 TW TW105114554A patent/TWI700276B/zh not_active IP Right Cessation
- 2016-05-11 HR HRP20190089TT patent/HRP20190089T1/hr unknown
- 2016-05-11 EA EA201792262A patent/EA032363B1/ru not_active IP Right Cessation
- 2016-05-11 LT LTEP16721817.1T patent/LT3294719T/lt unknown
- 2016-05-11 AR ARP160101356A patent/AR104591A1/es not_active Application Discontinuation
- 2016-05-11 DK DK16721817.1T patent/DK3294719T3/en active
- 2016-05-11 MY MYPI2017001636A patent/MY184965A/en unknown
- 2016-05-11 PE PE2017002418A patent/PE20180039A1/es unknown
- 2016-05-11 PT PT16721817T patent/PT3294719T/pt unknown
- 2016-05-11 EP EP16721817.1A patent/EP3294719B1/en active Active
- 2016-05-11 GE GEAP201914622A patent/GEAP201914622A/en unknown
- 2016-05-11 TR TR2019/01228T patent/TR201901228T4/tr unknown
- 2016-05-11 HK HK18111409.2A patent/HK1252099B/en unknown
- 2016-05-11 UA UAA201711057A patent/UA120779C2/uk unknown
- 2016-05-11 ME MEP-2019-11A patent/ME03312B/me unknown
- 2016-05-11 KR KR1020177032520A patent/KR102551429B1/ko active Active
- 2016-05-11 IL IL255466A patent/IL255466B/en unknown
- 2016-05-11 MX MX2017014390A patent/MX375469B/es active IP Right Grant
- 2016-05-11 CN CN201680025327.1A patent/CN107567440B/zh active Active
- 2016-05-11 ES ES16721817T patent/ES2709362T3/es active Active
- 2016-05-11 SM SM20190053T patent/SMT201900053T1/it unknown
- 2016-05-11 RU RU2017139002A patent/RU2713889C2/ru active
- 2016-05-11 RS RS20190108A patent/RS58263B1/sr unknown
- 2016-05-11 JP JP2017558957A patent/JP6731001B2/ja active Active
- 2016-05-11 SI SI201630176T patent/SI3294719T1/sl unknown
- 2016-05-11 GE GEAP201614622A patent/GEP20197020B/en unknown
- 2016-05-11 MA MA043397A patent/MA43397A/fr unknown
- 2016-05-11 CA CA2984615A patent/CA2984615C/en active Active
- 2016-05-11 BR BR112017024039A patent/BR112017024039B8/pt active IP Right Grant
- 2016-05-11 AU AU2016259762A patent/AU2016259762B2/en active Active
- 2016-05-12 US US15/152,902 patent/US10287261B2/en active Active
-
2017
- 2017-10-27 ZA ZA2017/07337A patent/ZA201707337B/en unknown
- 2017-11-02 CO CONC2017/0011295A patent/CO2017011295A2/es unknown
- 2017-11-03 DO DO2017000260A patent/DOP2017000260A/es unknown
- 2017-11-03 SV SV2017005560A patent/SV2017005560A/es unknown
- 2017-11-07 PH PH12017502028A patent/PH12017502028A1/en unknown
- 2017-11-09 CL CL2017002844A patent/CL2017002844A1/es unknown
- 2017-11-10 EC ECIEPI201774919A patent/ECSP17074919A/es unknown
-
2019
- 2019-01-24 CY CY20191100089T patent/CY1121171T1/el unknown
- 2019-03-06 US US16/294,647 patent/US11279682B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001368A1 (es) | Composiciones que comprenden cepas bacterianas | |
| MX2018003196A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| CL2017003389A1 (es) | Composiciones de pienso para animales y usos de las mismas. | |
| EP3585278C0 (en) | TARGETING INSTRUMENTS AND SYSTEMS | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| MX380250B (es) | Compuestos farmacéuticos inhibidores de cinasa chk-1. | |
| CU20190006A7 (es) | Composiciones para inhibir masp-3 | |
| DOP2017000260A (es) | Piroglutamato de vortioxetina | |
| MX375378B (es) | Formulaciones de anticuerpos anti-pdl1. | |
| MA40938A (fr) | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps | |
| UA124919C2 (uk) | Швидкодіючі композиції інсуліну | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| BR112017016465A2 (pt) | composto heterocíclico e composição farmacêutica que o compreende | |
| MX2018007390A (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| MX2018008302A (es) | Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. | |
| CY1122287T1 (el) | Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ | |
| MX2017013073A (es) | Inhibidores de grelina o-aciltransferasa. | |
| MX2017013072A (es) | Inhibidores de grelina o-aciltransferasa. | |
| MX383460B (es) | Derivados peptidicos novedosos y sus usos. | |
| ES2747993T8 (es) | Composiciones farmacéuticas de liberación prolongada de levetiracetam |